Plain-English translation of NCT06839976 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing , a new type of cell therapy for young people with severe lupus that hasn't responded to traditional treatments. The therapy works by taking your own immune cells, modifying them in the laboratory to target specific cells that drive lupus, and then giving them back to you through an infusion. Early results suggest this approach may help people achieve remission without needing as many immunosuppressive medications.
Standard lupus treatments don't work well enough for everyone, and many patients struggle with serious side effects from long-term use of immune-suppressing drugs. This medication offers a potentially deeper and longer-lasting way to control the disease by targeting the root cause rather than just managing symptoms.
You likely qualify if…
You likely don't qualify if…
You will undergo a screening period to confirm your eligibility, then have your own immune cells collected through a process similar to donating blood plasma. These cells are sent to the laboratory where they are modified to recognize and attack the cells driving your lupus. After chemotherapy to prepare your body, you will receive an infusion of these modified cells back into your bloodstream. You will then be closely monitored with regular clinic visits and blood tests to track how well the treatment works and watch for any side effects.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States